# Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older

> **NCT02526745** · PHASE1,PHASE2 · COMPLETED · sponsor: **Beijing Chaoyang District Centre for Disease Control and Prevention** · enrollment: 440 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** the vaccine with high doses of virus content between 4.7～5.0 lgPFU
- **BIOLOGICAL:** the vaccine with low doses of virus content between 4.7～5.0 lgPFU
- **BIOLOGICAL:** the vaccine with high doses of virus content between 4.3～5.0 lgPFU
- **BIOLOGICAL:** the vaccine with middle doses of virus content between 4.3～5.0 lgPFU
- **BIOLOGICAL:** the vaccine with low doses of virus content between 4.3～5.0 lgPFU
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT02526745
- **Lead sponsor:** Beijing Chaoyang District Centre for Disease Control and Prevention
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2016-07
- **Final completion:** —
- **Target enrollment:** 440 (ACTUAL)
- **Last updated:** 2016-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02526745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02526745, "Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02526745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*